Introduction: The aim of this study is to examine whether moderate hiperhomocysteinemia is an independent risk factor for cerebral infarction. Methods: We have measured homocysteine levels in 50 patients with ischemic stroke during acute phase and postacute phase, 50 patients diagnosed with vascular dementia and healthy group of 50 subjects. Homocysteine concentration in serum was measured, on the basis of À uorescent polarisation measuring.
Introduction
Th e ischemic stroke (IS) is major cause of global disability and is the second most common cause of death worldwide. Elevated tolal plasma homocysteine level is common in the old age and is well-established risk factor for cardiovascular and cerebrovascular disease (1) . Th e amino acid homocysteine occurs by demethylation of methionine, essential amino acid, which in enters the human body with food. It is found in the plasma mainly in the oxidized state (homocysteine or homocysteine-cysteine disulfi de) and bound to proteins, mostly albumin (2, 3) . It was fi rst described in work of Butz and Vigneaud who have synthesized amino acid homocysteine in a reaction of strong concentrated acid with methionine. (4) . Based on fi ndings observed in patients with homocystinuria, McCully postulated that hyperhomocysteinemia may play a role in the pathogenesis of atherotrombotic vascular disease (5) . Elevated levels of homocysteine can therefore cause damage to several key pathways in the central nervous system, either directly or by changing the methylation potential. Th e hyperhomocysteinemia is very common in patients with stroke and is suggested to be an independent risk factor for the disease (6, 7) . Th e elevated concentrations of homocysteine are responsible for occurrence of atherosclerosis in at least 3 ways: 1) toxic eff ect of homocysteine in endothelium of arteries, 2) interference of homocysteine with clotting factors and 3) oxidation of low-density lipoprotein (LDL). Although there are data on homocysteine metabolism, the pathogenesis of hyperhomocysteinemia is still not clear. Homocysteine is turned into a methionine by remethylation; methyl group donor in most tissues is 5-methyltetrahydrofolate, nevertheless betaine is donor in the liver, kidney and eye lens. Th e reaction is catalyzed by methionine-synthase (MS) with vitamin B12 as a cofactor. Tetrahydrofolate incurred converts to 5,10-methyl-tetrahydrofolate with the enzyme methylene-tetrahydrofolate reductase (MTHFR) and then in 5-methyl-tetrahydrofolate. Another pathway of homocysteine metabolism is trans-sulphuration pathway in which homocysteine with serine turns to cystathionine under the action of enzymes cistationine-β-synthase (CBS) and cofactor vitamin B6. Aft er that cystathionine goes into cysteine under the infl uence of the enzyme γ-cystathionase (GCT) (8) (9) (10) . Homocysteine metabolism is regulated by the concentration of methionine that is normally used for protein synthesis and synthesis of S-adenosyl-methionine. Homocysteine lies at the intersection two of metabolic pathways, transsulphuration pathway and remethylation cycle. Current availability of methionine determines the pathway by which the homocystein will be metabolized. Decrease of folic acid and vitamin B12 leads to increase of homocysteine and decreases the remethylation of homocysteine (11, 12) . It could be postulated that elevated total homocysteine is a risk factor for atherotrombic stroke in particular. Moreover, there is a debate whether homocysteine is a causative risk factor in stroke and myocard infarction or is merely a secondary marker of risk in survivors (13) . Date regarding to homocysteine concentration immediately aft er stroke would help to resolve this question, because the observation of a raised homocysteine at this time would be more suggestive of a causal association that the occurrence of hyperhomocysteinemia in survivous sampled at a time distant from the event.
Methods

Patients
Th e investigation included 100 patients and 50 healthy subjects. 250 blood samples were collected during 2008 and 2009. All investigation was done respecting ethical standards by the Helsinki Declaration. Th e patients were hospitalised at Clinic of Neurology, Clinical Centre University of Sarajevo, Old home "Nedžarići, and Old home "Ernest Grin". Th e patients group included patients with fi rst ischemic stroke (50 subjects) and vascular dementia (50 subjects). Th e control group included 50 healthy subjects who were protégé at Old home "Nedžarići". Criteria for inclusion of patients with stroke and vascular dementia were: diagnosis of fi rst ischemic stroke determined by computerized tomography (CT), presence of vascular dementia identifi ed using computerized tomography (CT) and nuclear magnetic resonance (NMR), "Hachinski ischemic score" grater or equal to 7 for patients with vascular dementia, age over 65 years for both sexes, two weeks of hospital stay for patients with ischemic stroke, stroke in patients with vascular dementia in last three to six years. Th e study inclusion criteria for control group were: excluded ischemic stroke or vascular dementia by computed tomography (CT) and nuclear magnetic resonance (NMR), age over 65 years for both sexes, excluded kidney, heart or vascular diseases. Criteria for exclusion from the study, for both patients and controls, were: diseases that are associated with impaired renal function and renal failure (determined by serum creatinine concentration), chronic infl ammatory disease, rheumatoid arthritis, SLE, multiple sclerosis and psoriasis, acute lymphoblastic leukaemia, intestinal disorders atrophic gastritis, Crohn's disease and ulcerative colitis, Hypothyroidism, patients on treatment with methotrexat, carbamazepine, phenytoin, and theophylline. Th e blood samples were collected at the mornings before the fi rst meal. For the group of 50 patients diagnosed with the fi rst ischemic brain stroke, blood samples were taken during the acute phase (initial 24-48 hospitalization hours), and post-acute phase (aft er 7±1 days, and aft er 11-14 hospitalization days). For the group of 50 patients diagnosed with vascular dementia developed as a consequence of ischemic brain stroke, i.e. of many small ischemic focus of various age. Th e study included 27 men and 23 women in control group. Th ere were 27 males and 23 females in the group with ischemic stroke and 28 men and 22 women in the group with vascular dementia. By analyzing the history of disease we collected data about radiological examinations of brain computed tomography (CT) and brain nuclear magnetic resonance (NMR). 92% (46) of patients suff ering from ischemic stroke had the diagnosis ICV per trombosim and at 8% (4) patients the diagnosis was ICV per emboliam. Level of albumin was obtained from patients history and was in normal range (35-50g/L). Th e value of serum homocysteine concentration was determined using AxSYM (Abbott), based on measurements of fl uorescence polarization immunoassay (FPIA) technology. Th e reaction principle is conversion of homocystine, mixed disulfi de and protein-bound forms of homocysteine in the sample to form of free homocysteine by the use of dithiothreitol (DTT). Aft er that, free homocysteine is converted to S-adenosyl-Lhomocysteine (SAH). Under physiological conditions, SAH hydrolases convert SAH to homocysteine. Levels of L-homocysteine are determined in human serum. Normal homocysteine concentration in serum is 3.36-20.44 μmol/L for women and 5.90-16 μmol/L for men. Th e creatinin was determined using automatic analyzer Dimension (Dade Behring). Method for determination of creatinine is a modifi cation of the kinetic reaction of Jaff ee. Th e reference value for serum creatinine concentration is 45-115 μmol/ L. Th e patient samples of blood were collected in serum separation Vacutainer test tubes (Beckton Dickinson, Rutherford, NJ 07,070 U.S.) in volume of 3.5 mL. We used test tubes with gel. Aft er collection, samples were placed in ice and, aft er 30 to 60 minutes serum samples were obtained by centrifugation at 3000 rpm using centrifuge (Sigma 4-10). Aft er centrifuging, concentration of homocysteine and creatinine in sera were determined. All subjects (patients and controls) had concentration of creatinine in reference values.
Statistical analysis
Th e results were statistically analyzed using SPSS version 11 and Microsoft Offi ce Excel 2003. Average values (χ), standard deviation (SD) and Spearman correlation coeffi cient (r) were calculated, as well as Wilcoxon signed ranks and Mann-Whitney test with statistical signifi cance level of 0.05 (P <0.05).
Results
Th e average age in the control group was 69.34 years. In the group with vascular dementia, the average age was 73.74 years. Th e group with ischemic stroke had an average age of 70.12 years. Mean concentrations of homocysteine in patients aft er ischemic stroke (24-48 hours, 7 days and 14 days), patients with vascular dementia and control groups are shown in Table 1 . Th e average concentration of homocysteine and + / -SD in patients aft er ischemic stroke (24-48 hours, 7 days and 14 days), patients with vascular dementia and control groups are graphically show in Figure 1 . Th e homocysteine serum concentrations were increased during the acute phase to the post acute phase of ischemic stroke, as shown by results in Figure 2 . During hospitalization serum concentrations of homocysteine increased aft er seven days and then increased significantly aft er the fourteenth day. In the acute phase aft er 7 days of hospital treatment homocysteine concentration was increased for 1.54 μmol/L, aft er 14 days for 3.66 μmol/L compared to the concentration aft er the fi rst 24-48 hours. Between 7 and 14 days of treatment the concentration of homocysteine increases for 2.12 μmol / L. Analysis of distribution showed assimetrical distribution of homocysteine levels in patients with ischemic stroke, vascular dementia and control group. We used Wilcoxon signed ranks for comparison of serum homocysteine concentration in patients with ischemic brain stroke during acute phase and post-acute phase. Results are shown in Table 2 .
In serum homocysteine concentration 24-48 hours aft er the fi rst symptoms of ischemic stroke were signifi cantly diff ered from the concentration of homocysteine aft er 7 and 14 days of hospital treatment (p < 0.05). Th ere was a signifi cant diff erence between the average homocysteine concentration aft er 7 and 14 days of hospital treatment (p<0.05). Using Mann-Whitney U-test we made comparison of serum homocysteine between risk groups (ischemic stroke, vascular dementia) and control healthy group, the results are shown in Table 3 . According to Mann-Whitney test for α = 5%, the diff erence between concentrations of homocysteine in the acute phase of ischemic stroke and control healthy groups is not signifi cant. Th e same test for α = 5% has shown a signifi cant diff erence between concentrations of homocysteine in the acute phase of ischemic stroke and control group. Th e serum concentrations of homocysteine increase aft er 7 days and signifi cantly increased aft er 14 days of hospital treatment. We found signifi cant diff erence between concentrations of homocysteine in the acute and the post-acute phase of ischemic stroke and a group with vascular dementia (p<0.05). Th e concentration of serum homocysteine concentration was higher in the group with vascular dementia than in the group with ischemic stroke. Average serum concentrations of homocysteine in the group with vascular dementia was signifi cantly diff erent from control healthy group (p <0.05). Th e serum creatinene concentration was in reference value (45-115 μmol/ L) for all patients in risk groups and in control group. So we can exclude that serum concentration of homocysteine was increased for kidney demage. In the group of patients with vascular dementia, 52% (26 patients) had an extensive one stroke, 32% (16 patients) two strokes, 16% (8 patients), many small ischemic focus without ischemic stroke the results are shown in Figure 3. According to the Spearman correlation test, it was found a statistically signifi cant correlation between the number of strokes and concentrations of homocysteine in the serum of patients with vascular dementia of p <0.05 (correlation coeffi cient = 0.341, p = 0.015). Th e serum homocysteine concentration is increasing with number of strokes infarctions and more ischemic focus.
Discussion
Homocysteine is an independent risk factor for developing peripheral vascular, cerebrovascular and coronary heart disease. Th e mechanism by which the total homocysteine may cause vascular disease includes thrombosis, endothelial dysfunction and increased oxidation of LDH (low density cholesterol) (15) . About 50% of patients with hyperhomocysteinemia have vascular changes before ther thirty years of old (16) . Our study showed that the group of patients with ischemic stroke 30% (15 patients) had moderate hyperhomocysteinemia, from the total sample number it was 44 % of men and 13% of woman. Th e results of our study have shown that the mean concentration of homocysteine after 24-48 hours of hospital treatment was 13.27 μmol/L, aft er 7 days 14.81 μmol/L and 14 day 16.93 μmol/L in comparison to serum concentration in control group it was 10.49 μmol/L (Table 1) . At the post-acute phase of ischemic stroke aft er 7 days homocysteine increces for 1.54 μmol/L in compared to the concentration of homocysteine aft er the fi rst 24-48 hours of patients hospitalization. In our study, aft er 14 days of hospitalization of patients with ischemic stroke average homocysteine concentration was increased from 0.20 μmol/L to 20.42 μmol/L (average 3.66 μmol/L). Th e mean serum homocysteine concentration increases during fi rst to second week for 2.12 μmol/L. Th e results are shown in Figure 1 and Figure 2 . In a two retrospective studies, the British regional health study and the Framingham Heart Study, that there is independent association betwe- en serum homocysteine and the incidence of ischemic stroke if homocysteine concentrations were equal or greater than 15.4 μmol/L and homocysteine concentrations were equal or greater than 14.24 μmol/L. In the Rotterdam study it is showed a signifi cant increase in stroke risk with increasing serum homocysteine levels above 18.6 μmol/L (17) . High concentrations of homocysteine are closely correlated with the risk of silent stroke (18) . It was concluded that homocysteine is an independent risk factor for stroke in people older than sixty years, and homocysteine concentrations above 14 μmol/L increased to 80% risk of stroke (19) . If the concentration of serum homocysteine increases for 1 μmol/L the risk for new ischemic stroke increases for 22% (20) . Th e increase of homocysteine concentration for 5 μmol/Lincreased the risk for coronary heart disease 1.6 times for men and 1.8 times for women, and cerebrovascular disease increases the risk for both sexes 1.5 times (21) . It is believed that during the fi rst week aft er ischemic stroke homocysteine concentration increases for about 10% (22) . Our research has shown that during the fi rst week aft er ischemic stroke, homocysteine concentration increases for about 11.6%. Using Wilcoxon signed ranks the mean value of serum homocysteine in patients with ischemic stroke aft er 24-48 hours was signifi cantly diff erent than the mean values of homocysteine aft er 7 and 14 days of patients hospitalisation with signifi cance of p < 0.05. Our result have show using same test that there was a signifi cant diff erence between the average homocysteine concentration aft er 7 and 14 days of hospital treatment (p < 0.05) ( Table 2 ). According to our results using the Mann-Whitney test average concentrations of homocysteine in the acute phase of ischemic stroke aft er 24-48 hours showed no signifi cant diff erence with control group. A signifi cant increase in homocysteine concentration occurs only in the acute phase in which there was a signifi cant diff erence compared to the control group (Table 3) . Th e results have shown that it is evident that the concentration of serum homocysteine increase aft er stroke. Th ere are two possible explanations for the change in serum homocysteine concentration aft er acute phase and during the pos-tacute phase of ischemic stroke recovery:
• Th e acute phase of ischemic stroke following stress which leads to short-term decrease in serum homocysteine. Damage to cerebral tissue increases the production of oxygen radicals, increases oxidative stress, leading to possible subsequent changes in the degree of elimination of thiols, including homocysteine.
• Serum homocysteine increases aft er the acute phase of ischemic stroke as a reason of folate and vitamins B6 or B12 defi ciency which is particularly common in elderly people. Impairment of renal function also leads to increased concentrations of homocysteine (23) .
Th erefore, we excluded from our study patients with a high concentration of creatinine. Th e fi rst early signs of dementia are presented with a reduction in the volume of brain mass and the occurrence of silent stroke (4). In our study, another group of patients who are determined homocysteine concentration had vascular dementia as a consequence of ischemic stroke. At group with vascular dementia hyperhomocysteinemia was present in 62% (81.4% men and 39.1% women). According to our results in the group of patients with vascular dementia, the average homocysteine concentration was 20.39 μmol / L. Homocysteine in the group of patients with vascular dementia was signifi cantly higher than in the group with ischemic stroke and control group (Table 1) . According to Mann-Whitney test for α = 5%, a signifi cant diff erence between concentrations of homocysteine in the acute phase of ischemic stroke and vascular dementia. Using the same test for α = 5%, a signifi cant diff erence between concentrations of homocysteine in the postacute phase of ischemic stroke and concentrations of homocysteine in vascular dementia. Comparing the results showed signifi cant diff erences between the average concentrations of homocysteine with vascular dementia group and control group (p < 0.05) ( Table 3 ). In the group of patients with vascular dementia, 52% (26 patients) had one extensive stroke, 32% (16 patients) two, and 16% (8 patients), many small ischemic focus without ischemic stroke (Figure 3 ). We got signifi cant correlation (Spearman correlation test) between the number of strokes and concentrations of homocysteine in the serum of patients with vascular dementia. Th e results of our study showed that with increasing number of attacks increased concentrations of homocysteine what can lead to evolution of vascular dementia aft er ischemic stroke. Our results shown that more males has hyperhomocysteinemia in relation to females, so they have move prevalence for developing new ischemic stroke or vascular dementia. If homocysteine concentration increases above 14 μmol/L increased the risk for Alzheimer's disease or vascular dementia for 4.6 times higher than in patients in who has concentration of homocysteine is less than 11 μmol/L (24). According to our results, homoysteine concentration increasing from acute to post-acute phase at patients with ischemic stroke and patients with vascular dementia have higher concentration of homocysteine then patients with ischemic stroke.
Conclusion
Th e homocysteine could be an independent risk factor for development of cerebrovascular disease. Th e possible limitation of of our study are limited number of patients and we have not informations about concentration of homocysteine before ischemic brain stroke or vascular dementia. Hyperhomocysteinemia is present in about 30% (44% men and 13% females) of patients with ischemic stroke and in about 62% of patients with vascular dementia (81.4% men and 39.1% women). Th e concentration of homocysteine increases during 14 days of hospital treatment in comparison of homocysteine concentration 24-48 hours aft er ischemic stroke. Th e patients with elevated concentration of homocysteine aft er stroke have longer hospitalization than patients with reference value of homocysteine.
